Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00889044
Other study ID # SHEBA-08 -5397-SM-CTIL
Secondary ID
Status Recruiting
Phase Phase 3
First received April 26, 2009
Last updated April 26, 2009
Start date April 2009
Est. completion date June 2011

Study information

Verified date April 2009
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

Since the absorption of clopidogrel through the gastrointestinal tract is limited, we want to examine whether adding clopidogrel by chewing will overcome the limited gastrointestinal absorption, and hence will improve the prevention of platelet aggregation.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and Female older than 18 years old with non-ST myocardial infarction

Exclusion Criteria:

- Current treatment with anticoagulation medication, any type of cerebro vascular event in the past, active bleeding, active peptic ulcer disease, pregnant women, any inability to sign an informed consent of participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
clopidogrel by chewing
600 mg clopidogrel by chewing
Placebo
Placebo p.o

Locations

Country Name City State
Israel Sheba_medical_center Ramat-Gan
Israel Sheba Medical Center, Cardiac Institute Tel Hashomer

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (2)

Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 Jun 17;107(23):2908-13. Epub 2003 Jun 9. — View Citation

Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 Jun 29;109(25):3171-5. Epub 2004 Jun 7. Erratum in: Circulation. 2011 Oct 25;124(17):e459. Bienart, Roy [corrected to Beinart, Roy]. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Platelet aggregation and bleeding events 6 months Yes